论文部分内容阅读
目的:评价治疗急性脑梗塞用药方案的成本-效果。方法:收集急性脑梗塞病例201例,按用药方案不同分为丹红组、丹参川芎嗪组,观察疗效并进行成本效果分析。结果:两组治愈率之间比较无显著性差异(P>0.05);成本效果比分别为11.02、18.41。结论:丹红组方案治疗急性脑梗塞较好。
OBJECTIVE: To evaluate the cost-effectiveness of treatment regimens for acute cerebral infarction. Methods: A total of 201 cases of acute cerebral infarction were collected and divided into three groups: Danhong group and Ligustrazine group. The curative effect was observed and the cost-effectiveness analysis was conducted. Results: There was no significant difference between the two groups in the cure rate (P> 0.05). The cost-effectiveness ratios were 11.02 and 18.41 respectively. Conclusion: Danhong group is better for acute cerebral infarction.